| GLOIX | OSMAX | GLOIX / OSMAX | |
| Total Expense Ratio | 0.91 | 1.42 | 64% |
| Annual Report Gross Expense Ratio | 3.75 | 1.42 | 264% |
| Fund Existence | 19 years | 29 years | - |
| Gain YTD | -0.623 | 2.986 | -21% |
| Front Load | N/A | 6% | - |
| Min. Initial Investment | 1000 | 1000 | 100% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 6.32M | 2.34B | 0% |
| Annual Yield % from dividends | 1.87 | 1.43 | 131% |
| Returns for 1 year | 12.65 | -14.44 | -88% |
| Returns for 3 years | 27.97 | -12.11 | -231% |
| Returns for 5 years | 1.65 | -38.00 | -4% |
| Returns for 10 years | -27.08 | 2.72 | -997% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| WVAIX | 42.54 | 0.17 | +0.40% |
| Weitz Large Cap Equity-Institutional Cl | |||
| MSVVX | 5.53 | 0.02 | +0.36% |
| MetLife Small Company Equity Investor | |||
| SILVX | 19.42 | 0.05 | +0.26% |
| SGI US Large Cap Equity I | |||
| SHISX | 61.97 | 0.09 | +0.15% |
| BlackRock Health Sciences Opps Svc | |||
| PEGEX | 19.59 | -0.24 | -1.21% |
| PGIM Jennison Mid-Cap Growth R2 | |||